Syqe Medical Rolls Out ‘World’s 1st’ Metered-Dose Cannabis Inhaler

Pharmaceutical tech company Syqe Medical announced late last week that it received regulatory approval by the Israeli Health Ministry for what it called the “world’s first” pharmaceutical-grade cannabis inhaler.

Syqe Medical is launching the Syqe Inhaler after eight years of research and development, to enable physicians to prescribe precise dosages of medical cannabis, the company said in a statement.

“For too long, physicians who wish to treat [cannabis] patients have been without the most basic clinical knowledge on dosing, efficacy and adverse events of cannabis,” Perry Davidson, CEO and founder of Syqe Medical said in the statement. He added, “through our clinical trials, we were able to determine the recommended dosage of inhaled cannabis down to the microgram.”

The device uses a cartridge containing vaporization chips, which consist of “precise and uniform amount of raw cannabis flowers produced under pharmaceutical standards,” the company says. Its selective-dose technology allows for remote, personalized dosing of THC by a physician.

News of the device’s launch comes six months after the company raised $50 million in a financing round led by the Shavit Capital fund. According to a Globes report, this was the largest financing round ever for an Israeli medical cannabis firm.

The company, founded in 2011 by Davidson, aims to bring cannabis to its full medical potential and plans to apply the Syqe platform to other medical plants in the future.

The inhalers have already been in use for over a year at Haifa’s Rambam Hospital, and will now be available for purchase by licensed patients in Israel, following Syqe’s goal to “transform medical cannabis into a mainstream medical treatment.”

“This launch marks the beginning of a new chapter in pain treatment,” Davidson said. “One in which physicians can confidently prescribe precise dosages of cannabis and patients can reap the rewards effectively and responsibly.”